MAIA Biotechnology grants Stan Smith 38,871 stock options

The options vest 100% on September 30, 2026, are exercisable beginning that day and expire September 30, 2036.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Stan Smith reported an award on September 30, 2026, of 38,871 stock options, beneficially owned through The Stan V. Smith Trust Dated 1993. The options cover 38,871 shares of common stock and carry a $1.18 per-share exercise price.

Insider Trade Summary

Grant/Award: 38,871 shares

Grant/Award 1 txn

Insider Smith Stan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1, F2	38,871	$0.00	$0.00

Holdings After Transaction: Stock Options — 38,871 contracts (Indirect, See footnote)

Footnotes (2)

1. F1. The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
2. F2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Key Figures

Stock options awarded: 38,871 options Common shares underlying options: 38,871 shares Exercise price: $1.18 per share +2 more

5 metrics

Stock options awarded 38,871 options Award reported September 30, 2026

Common shares underlying options 38,871 shares Shares underlying the stock options

Exercise price $1.18 per share Stock options

Vesting 100% On September 30, 2026, the grant date

Expiration date September 30, 2036 Stock options

Key Terms

2021 Equity Incentive Plan, beneficially owned, vest, exercisable

4 terms

2021 Equity Incentive Plan financial

"pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

beneficially owned regulatory

"beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

vest financial

"vest 100% on the date of the grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercisable financial

"are exercisable beginning as of that date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MAIA stock options did Stan Smith report, and what is their exercise price?

Stan Smith reported an award of 38,871 stock options, beneficially owned through The Stan V. Smith Trust Dated 1993. The options cover 38,871 shares of common stock and carry a $1.18 per-share exercise price.

When do Stan Smith's MAIA options vest and expire?

The options vest 100% on September 30, 2026, the grant date, and are exercisable beginning that day. They expire on September 30, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:19 PM Accepted by SEC EDGAR 10/02/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Stan

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.18	09/30/2026		A		38,871		09/30/2026(1)	09/30/2036	Common Stock	38,871	$0	38,871	I(2)	See footnote

Explanation of Responses:

1. The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

	/s/ Stan V. Smith	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)